Ajanta Pharma Limited — Others, 18-07-2025: Shareholders meeting

Ajanta Pharma's 46th Annual General Meeting concluded with all resolutions receiving strong shareholder approval. Investors voted to adopt the audited financial results for the year ended March 31, 2025, and ratified the interim dividend. Key leadership re-appointments, including Mr. Rajesh Mannalal Agrawal as Director and Mr. Madhusudan B. Agrawal as Executive Director & Vice-Chairman, were also approved. Additionally, the appointment of Secretarial Auditors and ratification of Cost Auditors' remuneration passed. This broad support highlights robust investor confidence in Ajanta Pharma's financial health and governance.